|
Ultrasound and motivational enhancement for prenatal smoking cessation Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Ultrasound and motivational enhancement for prenatal smoking cessation conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Ultrasound and motivational enhancement for prenatal smoking cessation Clinical research trials and Ultrasound and motivational enhancement for prenatal smoking cessation healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Ultrasound and motivational enhancement for prenatal smoking cessation. Ultrasound and motivational enhancement for prenatal smoking cessation Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Ultrasound and motivational enhancement for prenatal smoking cessation clinical trial. Human subjects often obtain the finest healthcare possible for their Ultrasound and motivational enhancement for prenatal smoking cessation condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "U" Clinical Trials Conditions > Ultrasound and motivational enhancement for prenatal smoking cessation  Ultrasound and motivational enhancement for prenatal smoking cessation
Ultrasound and motivational enhancement for prenatal smoking cessation
For Condition: Smoking,Pregnancy
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Robert Wood Johnson Foundation
Synopsis: The primary purpose of this randomized clinical trial is to test the efficacy of motivational enhancement (ME) therapy combined with biologic feedback (fetal ultrasound) for increasing smoking quit rates among low-income pregnant women considered resistant smokers. We hypothesize that ME along with biofeedback will increase the rate of validated smoking cessation at 8 months gestation by at least 10 percentage points above that produced by "Best Practice" (BP) counseling alone. This study will also examine reduction of smoking among non-quitters and maintenance of smoking cessation through 6 weeks postpartum among women who quit. Prenatal smoking is the leading preventable cause of low birth weight in the US. Reduction in smoking during pregnancy could result in significant improvements in pregnancy outcomes and reducing the cost of health care. There is evidence that low-intensity pregnancy smoking cessation programs may be inadequate for women who are more addicted, and at educational and economic disadvantage. Motivational enhancement strategies have shown considerable promise in the treatment of addictive behaviors. Physiological feedback highlighting prenatal effects of smoking and benefits of cessation has been found to enhance prenatal smoking cessation counseling. An intervention that combines motivational enhancement counseling and physiological feedback may have powerful effects beyond low-intensity interventions or usual counseling.
Details: Targeting women who deliver at one of the two UT-Houston teaching hospitals, Lyndon B. Johnson (LBJ) and Hermann Hospitals, pregnant women between 18 and 28 weeks gestation will be recruited from University of Texas/Harris County Hospital District-affiliated clinics, including Acres Homes, Aldine, Settegast, Baytown, and Squatty Lyons, LBJ and Hermann Hospital outpatient clinics, private practice OB/GYN's with patients who will deliver at Hermann Hospital, and area WIC (Women, Infants and Children) Program sites. Participants will be randomized to one of three groups, including 1) best practice (BP) counseling, 2) BP plus ultrasound, and 3) BP plus ultrasound plus motivational enhancement (ME) counseling. Counseling and cotinine testing will be performed at the University Clinical Research Center (UCRC) initially, at 34 weeks, and at 6 weeks postpartum. The primary outcome is the rate of smoking cessation among the women at 34 weeks gestation. Based on previous reports, projected quit rates for the 3 interventions, BP, BP + ultrasound, and BP + ultrasound + ME are .06, .12, and .20, respectively. A sample size of 360 will be necessary in order to observe these differences in quit rates. The chi-square test for trend in proportions will be used to determine statistical significance for this primary outcome.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: Pregnant women who are smokers, 16 years and older, 15-28 weeks gestation
Total Enrollment: 30
Location and Contact Information:
Overall Study Official:
JanetGroff, Principal Investigator,
University of Texas Medical School
Houston, Texas, 77030
United States
Additional Information:
Study ID Numbers: NCRR-M01RR02558-0153;
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013793
Other Pregnancy Studies:
1. Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
2. A Study of Nevirapine to Prevent HIV Transmission from Mothers to Their Babies
3. Studying Fetal Breathing Patterns
4. A Study of HIV Levels During Pregnancy and After Childbirth
5. A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
Related Studies:
Other Pregnancy Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Ultrasound and motivational enhancement for prenatal smoking cessation
|
|
|
|
|
|
|
|
